Latest Posts
About This Stock
More About This Stock
Read
Read
VistaGen Therapeutics Announces Positive Meeting With FDA Regarding Pivotal Phase 3 Study Of PH94B For Acute Treatment Of Anxiety In Patients With Social Anxiety Disorder
Article By:
TalkMarkets Newswire
Thursday, July 23, 2020 9:00 AM EDT
VistaGen and the FDA reached consensus on key aspects of a unique initial pivotal Phase 3 clinical trial of PH94B involving a single-event, laboratory-simulated public speaking challenge in adult patients with SAD.
VistaGen Therapeutics And EverInsight Therapeutics Enter Strategic Collaboration To Develop And Commercialize PH94B For Anxiety Disorders In Greater China, South Korea And Southeast Asia
Article By:
TalkMarkets Newswire
Thursday, June 25, 2020 8:03 AM EDT
The collaboration is intended to support Phase 3 development and commercialization of PH94B in key Asian markets. The agreement includes a $5 million upfront payment and development and commercial milestones up to $172 million.
